Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease

Journal of Pediatrics

Volumn 157, Issue 6, 2010, Pages

  Choueiter, Nadine F ^a   Olson, Aaron K ^a   Shen, Danny D ^a   Portman, Michael A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

AAP; AHA; American Academy of Pediatrics; American Heart Association; C reactive protein; CRP; Intravenous immunoglobulin; IVIG; JIA; Juvenile idiopathic arthritis; Kawasaki disease; KD; LAD; Left anterior descending; RCA; Right coronary artery; TB; Tuberculosis

Indexed keywords

ACETYLSALICYLIC ACID; ETANERCEPT; IMMUNOGLOBULIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHILD; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DILATATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; OPEN STUDY; OTITIS MEDIA; PHOTOPHOBIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 78449280363     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2010.06.014     Document Type: Article

References (33)

1. J.W. Newburger, M. Takahashi, M.A. Gerber, M.H. Gewitz, L.Y. Tani, and J.C. Burns Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association Pediatrics 114 2004 1708 1733 (Pubitemid 41754943)
2. A.H. Tremoulet, B.M. Best, S. Song, S. Wang, E. Corinaldesi, and J.R. Eichenfield Resistance to intravenous immunoglobulin in children with Kawasaki disease J Pediatr 153 2008 117 121
3. C.A. Wallace, J.W. French, S.J. Kahn, and D.D. Sherry Initial intravenous gammaglobulin treatment failure in Kawasaki disease Pediatrics 2000 105 E78
4. J.C. Burns, E.V. Capparelli, J.A. Brown, J.W. Newburger, and M.P. Glode Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group Pediatr Infect Dis J 17 1998 1144 1148
5. B.A. Lang, E.D. Silverman, R.M. Laxer, V. Rose, D.L. Nelson, and L.A. Rubin Serum-soluble interleukin-2 receptor levels in Kawasaki disease J Pediatr 116 1990 592 596
6. S. Furukawa, T. Matsubara, Y. Umezawa, K. Okumura, and K. Yabuta Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease J Pediatr 124 1994 721 725
7. M.B. Son, K. Gauvreau, L. Ma, A.L. Baker, R.P. Sundel, and D.R. Fulton Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006 Pediatrics 124 2009 1 8
8. A.S. Paller, E.C. Siegfried, R.G. Langley, A.B. Gottlieb, D. Pariser, and I. Landells Etanercept treatment for children and adolescents with plaque psoriasis N Engl J Med 358 2008 241 251
9. D.S. Yim, H. Zhou, M. Buckwalter, I. Nestorov, C.C. Peck, and H. Lee Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis J Clin Pharmacol 45 2005 246 256
10. B.W. McCrindle, J.S. Li, L.L. Minich, S.D. Colan, A.M. Atz, and M. Takahashi Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements Circulation 116 2007 174 179
11. D.J. Lovell, E.H. Giannini, A. Reiff, G.D. Cawkwell, E.D. Silverman, and J.J. Nocton Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group N Engl J Med 342 2000 763 769
12. A. Sekikawa, H. Ueshima, T. Kadowaki, A. El-Saed, T. Okamura, and T. Takamiya Less subclinical atherosclerosis in Japanese men in Japan than in white men in the United States in the post-World War II birth cohort Am J Epidemiol 165 2007 617 624
13. J.W. Newburger, L.A. Sleeper, B.W. McCrindle, L.L. Minich, W. Gersony, and V.L. Vetter Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease N Engl J Med 356 2007 663 675
14. A.C. Lau, T.T. Duong, S. Ito, and R.S. Yeung Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease Arthritis Rheum 60 2009 2131 2141
15. J.S. Hui-Yuen, T.T. Duong, and R.S. Yeung TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease J Immunol 176 2006 6294 6301
16. A.C. Lau, T.T. Duong, S. Ito, and R.S. Yeung Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease Arthritis Rheum 58 2008 854 863
17. Y. Inoue, Y. Okada, M. Shinohara, T. Kobayashi, T. Kobayashi, and T. Tomomasa A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome J Pediatr 149 2006 336 341
18. J.C. Burns, B.M. Best, A. Mejias, L. Mahony, D.E. Fixler, and H.S. Jafri Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease J Pediatr 153 2008 833 838
19. I. Nestorov Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34 2005 12 18
20. I. Nestorov Clinical pharmacokinetics of tumor necrosis factor antagonists J Rheumatol Suppl 74 2005 13 18
21. S.R. Ford, A. Rao, and L. Kochilas Giant coronary artery aneurysm formation following meningococcal septicaemia Pediatr Cardiol 28 2007 300 302
22. E. Husain, and E. Hoque Meningoencephalitis as a presentation of Kawasaki disease J Child Neurol 21 2006 1080 1081
23. B. Killingley, V. Carpenter, K. Flanagan, and G. Pasvol Pneumococcal meningitis and etanercept - chance or association? J Infect 51 2005 E49 E51
24. G. La Montagna, and G. Valentini Listeria monocytogenes meningitis in a patient receiving etanercept for Still's disease Clin Exp Rheumatol 23 2005 121
25. E.S. Chung, M. Packer, K.H. Lo, A.A. Fasanmade, and J.T. Willerson Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial Circulation 107 2003 3133 3140
26. L. Gullestad, and P. Aukrust Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches Am J Cardiol 95 2005 17 23C discussion 38-40C
27. A. Nesbitt, G. Fossati, M. Bergin, P. Stephens, S. Stephens, and R. Foulkes Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents Inflamm Bowel Dis 13 2007 1323 1332
28. B. Bozkurt, G. Torre-Amione, M.S. Warren, J. Whitmore, O.Z. Soran, and A.M. Feldman Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure Circulation 103 2001 1044 1047
29. A. Deswal, B. Bozkurt, Y. Seta, S. Parilti-Eiswirth, F.A. Hayes, and C. Blosch Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure Circulation 99 1999 3224 3226
30. A.M. Manadan, K. Joyce, W. Sequeira, and J.A. Block Etanercept therapy in patients with a positive tuberculin skin test Clin Exp Rheumatol 25 2007 743 745
31. T. Bongartz, A.J. Sutton, M.J. Sweeting, I. Buchan, E.L. Matteson, and V. Montori Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 2006 2275 2285
32. D.J. Lovell, A. Reiff, N.T. Ilowite, C.A. Wallace, Y. Chon, and S.L. Lin Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis Arthritis Rheum 58 2008 1496 1504
33. M. Gibaldi, and D. Perrier Pharmacokinetics 1975 M Dekker New York